ClinicalTrials.gg
RecruitingNCT06405945Updated May 9, 2024

Cervical Cancer Susceptible Population Classification

An observational study in Cervical Cancer Susceptible Population Classification, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-09.

Sponsored by Anhui Provincial Hospital · Observational

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
Female
01

Study summary

Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.

02

Conditions studied

  • Cervical Cancer Susceptible Population Classification
03

In context

Lead sponsor

Anhui Provincial Hospital is the lead sponsor of 131 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

HPV positive person at average risk of cervical cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged >=18 years at time of consent
  2. Intended to undergo screening colposcopy
  3. Considered by a physician or healthcare provider as being of "average risk" for cervical cancer
  4. Willing to consent to blood draw cervical disease treatments
  5. Willing to sonsent to follow-up for five years as per protocol

Exclusion criteria

Exclusion Criteria:

  1. History of cervical cancer
  2. History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)
  3. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.
  4. Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
  5. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal

    HPV negative, TCT negative

    Genetic: PCR and sequence

  • LSIL

    HPV postive, TCT: CIN I or Colposcopy LSIL

    Genetic: PCR and sequence

  • HSIL

    HPV postive, TCT: CIN II-III or Colposcopy HSIL

    Genetic: PCR and sequence

  • cervical cancer

    HPV positive, Histopathology: cervical cancer

    Genetic: PCR and sequence

Interventions

  • GeneticPCR and sequence

    sequence the mutatation SNPs

06

What researchers measure

Primary outcomes

  1. Evalutaiton of the SNPs test in an average cervical cancer patients screening episode

    Time frame: two years

Secondary outcomes

  1. Classified susceptied person into different ladders

    Time frame: two years

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of USTC
    Hefei, Anhui 230001, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06405945
Responsible party
Sponsor
First posted
May 9, 2024
Start date
May 1, 2024
Primary completion
Apr 30, 2034 (estimated)
Completion
Jun 2036 (estimated)
Last update
May 9, 2024

Study contacts

Yingying Wang, Doctor
Contact
yingyingwang@ustc.edu.cn
18652270921
Tingting Zhao, Master
Contact
heyppy@163.com
17333296213
Yingying Wang, Doctor
study chair · The First Affiliated Hospital of University of Science and Technology of China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion